SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Caplin Point Laboratories surges on commencing production at injectable plant in Tamil Nadu

27 Mar 2014 Evaluate

Caplin Point Laboratories is currently trading at Rs. 175.50, up by 8.35 points or 5.00% from its previous closing of Rs. 167.15 on the BSE.

The scrip opened at Rs. 166.00 and has touched a high and low of Rs. 175.50 and Rs. 163.15 respectively. So far 30687 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 180.60 on 21-Mar-2014 and a 52 week low of Rs. 43.15 on 28-Jun-2013.

Last one week high and low of the scrip stood at Rs. 180.60 and Rs. 164.00 respectively. The current market cap of the company is Rs. 265.18 crore.

The promoters holding in the company stood at 57.18% while Institutions and Non-Institutions held 0.09% and 42.74% respectively.

Caplin Point Laboratories has commenced commercial Production at its state of art injectable Plant near Gummidipoondi, Tamil Nadu on March 27, 2014 to cater regulated markets USA, EU, Brazil, South Africa etc. This will now enable export of these products to Semi regulated and non regulated markets.

The Company has initiated the process of submitting required documents for obtaining approval from regulatory bodies such as UKMHRA, ANVISA, BRAZIL, USFDA, EUGMP which would enable export of Injectables in various dosage forms to the regulated markets besides offering contract manufacturing for export to these markets.

Caplin Point Laboratories is engaged in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.

Caplin Point Lab Share Price

1754.25 -18.25 (-1.03%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×